Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;31(9):944-952.
doi: 10.1002/pds.5491. Epub 2022 Jun 21.

Systematically exploring repurposing effects of antihypertensives

Affiliations

Systematically exploring repurposing effects of antihypertensives

Zach Shahn et al. Pharmacoepidemiol Drug Saf. 2022 Sep.

Abstract

With availability of voluminous sets of observational data, an empirical paradigm to screen for drug repurposing opportunities (i.e., beneficial effects of drugs on nonindicated outcomes) is feasible. In this article, we use a linked claims and electronic health record database to comprehensively explore repurposing effects of antihypertensive drugs. We follow a target trial emulation framework for causal inference to emulate randomized controlled trials estimating confounding adjusted effects of antihypertensives on each of 262 outcomes of interest. We then fit hierarchical models to the results as a form of postprocessing to account for multiple comparisons and to sift through the results in a principled way. Our motivation is twofold. We seek both to surface genuinely intriguing drug repurposing opportunities and to elucidate through a real application some study design decisions and potential biases that arise in this context.

Keywords: antihypertensives; causal inference; drug repurposing; hierarchical models.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Comparative effectiveness results of the antihypertensive treatments for A, heart failure, B, acute myocardial infarction, C, ischemic stroke, D, hemorrhagic stroke, and E, cardiac dysrhythmias. The cumulative incidence rate is measured at 1 year after baseline. The results use the single outcome pooling method

References

    1. James PA, Oparil S, Carter BL, et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507520. doi:10.1001/jama.2013.284427 - DOI - PubMed
    1. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393‐404. doi:10.1111/j.1524-6175.2002.02045.x - DOI - PubMed
    1. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first‐line antihypertensive drug classes: a systematic, multinational, large‐scale analysis. Lancet. 2019;394(10211):1816‐1826. doi:10.1016/S0140-6736(19)32317-7 - DOI - PMC - PubMed
    1. Chen R, Suchard MA, Krumholz HM, et al. Comparative first‐line effectiveness and safety of ACE (angiotensin‐converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591‐603. doi:10.1161/HYPERTENSIONAHA.120.16667 - DOI - PMC - PubMed
    1. Walker VM, Davies NM, Martin RM, Kehoe PG. Comparison of antihypertensive drug classes for dementia prevention. Epidemiology. 2020;31(6):852‐859. doi:10.1097/EDE.0000000000001245 - DOI - PMC - PubMed

Publication types

Substances